Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-C: Tremelimumab and Chemotherapy + Durvalumab in Stage III NSCLC
NCT04585490Phase 3Recruiting
- Sponsor
- Stanford University
- Start
- Aug 2021
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tremelimumab, carboplatin, pemetrexed, Paclitaxel Micelles for Injection, Cisplatin micelle injection (HA132) in non-small cell lung cancer (NSCLC), sponsored by Stanford University. Started Aug 2021; status: recruiting.
02
Drugs
tremelimumabcarboplatinpemetrexedPaclitaxel Micelles for InjectionCisplatin micelle injection (HA132)
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04585490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585490.